Compare GDRX & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDRX | REPL |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.9M | 781.3M |
| IPO Year | 2020 | 2018 |
| Metric | GDRX | REPL |
|---|---|---|
| Price | $2.19 | $7.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $4.78 | ★ $11.13 |
| AVG Volume (30 Days) | ★ 3.5M | 1.3M |
| Earning Date | 02-25-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $800,651,000.00 | N/A |
| Revenue This Year | $2.35 | N/A |
| Revenue Next Year | $2.53 | N/A |
| P/E Ratio | $25.20 | ★ N/A |
| Revenue Growth | ★ 1.30 | N/A |
| 52 Week Low | $2.10 | $2.68 |
| 52 Week High | $5.81 | $14.80 |
| Indicator | GDRX | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 54.23 |
| Support Level | $2.14 | $7.43 |
| Resistance Level | $2.43 | $7.93 |
| Average True Range (ATR) | 0.19 | 0.43 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 21.37 | 93.53 |
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.